Maze Therapeutics, Inc. (MAZE) Misses Q2 EPS by 15c

Maze Therapeutics, Inc. (NASDAQ: MAZE) reported Q2 EPS of ($0.77), $0.15 worse than the analyst estimate of ($0.62).

For earnings history and earnings-related data on Maze Therapeutics, Inc. (MAZE) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Future Money Acquisition gets Nasdaq notice over late 10-Q filing
• Northrop Grumman wins $143M in new U.S. defense contracts